Abstract:Aim: VDJ001 is a novel recombinant humanized monoclonal antibody against the anti-interleukin-6 receptor. As an analog of tocilizumab, it exhibited improved affinity and in vitro activity. Based on preclinical studies, a first-in-human clinical study was conducted to evaluate the safety, tolerability, and pharmacokinetics of VDJ001. Methods: This is a single-center, randomized, double-blinded, placebo-controlled phase I dose-escalation study conducted in healthy Chinese volunteers. Four cohorts were designed with dosages ranging from 1 to 8 mg/kg. There were equal numbers of female and male volunteers in each cohort. Enrolled subjects randomly received a single intravenous administration of VDJ001 or placebo (VDJ001: placebo = 4:1 in both female and male volunteers). Three sentinel volunteers in the 1 mg/kg cohort were first administered, and the treatment of the other seven volunteers was carried out after a safety assessment on D15. The following cohort was conducted only when the safety profile was evaluated as acceptable on D29 of the previous cohort. Samples for pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity were collected at specified time points and analyzed through validated methods. Adverse events and the results of the examination and laboratory were analyzed to assess the safety profile. Results: All cohorts were carried out according to the protocol. With the escalation of dosage, C max increased linearly, and AUC 0-t and AUC 0-∞ increased in a non-linear manner, while clearance decreased and t1/2 prolonged. Six volunteers who received VDJ001 tested ADA-positive, among whom one participant tested Nab-positive on D57. One volunteer in the placebo group tested ADA-positive but Nab-negative. CRP concentrations were not found to be correlated with the dosage. Both IL-6 and sIL-6R concentrations increased after the administration of VDJ001. All adverse events were mild to moderate in severity. No serious adverse events were reported in this study. No unexpected or clinically significant safety issues were found. Conclusion: The safety and tolerability of VDJ001 are acceptable with a single intravenous dosage of 1∼8 mg/kg. Further clinical trials are warranted.

PHARMACOKINETICS OF PEGYLATED RECOMBINAN NEW HUMAN INTERLEUKIN-6(PEG-rhIL-6)

Distribution and Excretion of the Pegylated Recombinant New Human Interleukin-6 (Peg-Rhil-6) in Rats

A Multiple-Dose Pharmacokinetics of Polyethylene Glycol Recombinant Human Interleukin-6 (Peg-Rhil-6) in Rats

The pharmacokinetic and pharmacodynamic properties of site-specific pegylated genetically modified recombinant human interleukin-11 in normal and thrombocytopenic monkeys.

Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models

Pharmacokinetics of PEG-rhG-CSF and rHSA-hG-CSF in mice determined with ELISA

Pharmacokinetics and Tissue Distribution of Human Recombinant Interleukin-2 in Mice.

Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol

Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist

Pharmaeokinetic Studies of PEG-dipeptide-TNF-α and in Rat Plasma by ~(125)I-Labeled and Extracting Methods

Pharmacokinetic Behavior of PEG-IFNα2b in SD Rats

Pharmacokinetics of PEGylated Recombinant Human Growth Hormone Injection in Healthy Volunteers by ELISA

Immunogenicity and Toxicokinetics Assessment of the Mono-Pegylated Recombinant Human Interleukin-11 in Cynomolgus Monkeys.

Pegylated Recombinant Human Tumor Necrosis Factor Alpha: Pharmacokinetics and Anti-Tumor Effects

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

PEGylation Markedly Enhances the in Vivo Potency of Recombinant Human Non-Glycosylated Erythropoietin: A Comparison with Glycosylated Erythropoietin

Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study

Tolerability, safety, and pharmacokinetics of a single intravenous administration of a novel recombinant humanized anti-interleukin-6 receptor monoclonal antibody in healthy Chinese volunteers

Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Gerilimzumab (GB224), a Recombinant Humanized Interleukin-6 Monoclonal Antibody, in Healthy Chinese Adults: A Randomized Controlled Dose-Escalation Study

Preclinical evaluation of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys

Pharmacokinetics and biodistribution of125I labeled rhTNT-IL2 in rats following a single intravenous injection